Page 14 - Ancer Immunotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict — before treatment begins — how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

An international panel of oncology and immunotherapy experts led by RCSI's Professor Jarushka Naidoo, has developed standardized definitions of the side effects of cancer immunotherapy to assist clinicians in treating patients.

BioNTech is expanding its cancer immunotherapy scope by partnering with OncoC4 on clinical testing of its lead drug. The antibody was designed to offer a safety edge over other CTLA-4-blocking drugs it's on track for a Phase 3 test in non-small cell lung cancer.

A symposium aiming to provide a better understanding of the tumor microenvironment, immune tolerogenic niches at cancer initiation, and novel immunotherapeutic strategies in head and neck cancer patients was featured at the 52nd Annual Meeting & Exhibition of the AADOCR, held in conjunction with the 47th Annual Meeting of the CADR.